China National Medical Products Administration approves BeiGene’s tislelizumab for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies

BeiGene

27 December 2019 - Second BeiGene discovered drug to receive regulatory approval, first in China.

BeiGene today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) as a treatment for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies. The new drug application was previously granted priority review by the NMPA. Following the recent approval of Brukinsa (zanubrutinib) by the U.S. FDA, tislelizumab is BeiGene’s first drug approved in China.

Developed by BeiGene scientists, tislelizumab is a humanised IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR, which is believed to play an essential role in activating phagocytosis in macrophages to minimise its negative impact on T effector cells.

Read BeiGene press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , China